All In Biotech

NDA 202667 · Thea Pharma

Cosopt Pf

Dorzolamide Hydrochloride, Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 1, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

19 Phase 3, 2 recruiting

FAERS reports

2,587

782 serious, 320 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2026.

COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT® administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14.1) ]. • COSOPT PF is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. • The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. ( 1 )

Mechanism: COSOPT PF is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 1, 2012 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • COSOPT PF · DORZOLAMIDE HYDROCHLORIDE EQ 2% BASE; TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2

Clinical trials

Interventional ClinicalTrials.gov studies with "Dorzolamide" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation513
  • ocular hyperaemia453
  • eye pruritus308
  • drug ineffective256
  • eye pain227
  • death210
  • eye swelling195
  • vision blurred139
  • lacrimation increased130
  • hypersensitivity128
  • dyspnoea101
  • glaucoma97

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20061
20082
200912
201030
201128
201217
2013101
201427
20157
201686
2017181
2018187
2019463
2020601
2021283
2022196
2023171
202462
202570
202660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cosopt PF (Dorzolamide/Timolol/PF)

2024 spending

$4.5M

Beneficiaries

3,125

12,769 claims

Per beneficiary

$1,445

$3.21 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$4,250,622
2024$4,516,110

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 322 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.